Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts rate Monopar Therapeutics “Moderate Buy”: Of 14 analysts, nine recommend buying, two strongly recommend buying, two advise holding and one recommends selling. The average 12-month price target is $118.67.
• Recent analyst actions were mixed but generally favorable: BTIG raised its target to $133, while Barclays and Morgan Stanley maintained overweight ratings with targets of $128 and $130, respectively; Wall Street Zen and Weiss Ratings issued sell ratings.
• MNPR opened at $107.72, near its 52-week high of $124.82, with a market capitalization of about $722.8 million. The company reported a quarterly loss of $0.62 per share, beating estimates by $0.02, while institutional investors own just 1.83% of shares.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $118.6667.

A number of research analysts recently weighed in on MNPR shares. Wall Street Zen lowered Monopar Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. BTIG Research raised their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Barclays reiterated an "overweight" rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday, August 13th. Finally, Morgan Stanley restated an "overweight" rating and set a $130.00 target price on shares of Monopar Therapeutics in a research note on Monday.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MNPR. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics during the third quarter worth approximately $28,000. BNP Paribas Financial Markets grew its position in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Sei Investments Co. increased its position in Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company's stock worth $415,000 after buying an additional 656 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $65,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $86,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Stock Down 2.8%

Shares of NASDAQ MNPR opened at $107.72 on Friday. The business's 50 day moving average price is $101.68 and its two-hundred day moving average price is $73.21. The company has a market cap of $722.80 million, a PE ratio of -49.64 and a beta of 1.47. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, research analysts anticipate that Monopar Therapeutics will post -2.94 EPS for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source